trending Market Intelligence /marketintelligence/en/news-insights/trending/mckj4wmf9bquplpvy0qu-w2 content esgSubNav
In This List

Spark Therapeutics sells $110M priority review voucher to Jazz Pharmaceuticals

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Spark Therapeutics sells $110M priority review voucher to Jazz Pharmaceuticals

Spark Therapeutics Inc. has sold a rare pediatric disease priority review voucher to Irish biopharmaceutical company Jazz Pharmaceuticals PLC for $110 million.

The U.S. Food and Drug Administration granted the priority review voucher to Spark's Luxturna, a one-time gene therapy to treat patients with biallelic RPE65 mutation-associated retinal dystrophy, an eye condition related to the light sensitive film at the back of the eye.

The voucher may be redeemed for priority review of a subsequent marketing application for a different product.

Philadelphia, Pa.-based Spark Therapeutics, is a biotechnology company, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases.